Abstract:Local control rates after SCRT (50 Gy) are very poor in advanced esophageal cancer. Most local failures (LF) occur in the GTV. HFRT allows for delivering a higher total dose without increasing late toxicity. We hypothesized that the use of HFRT boost to the GTV after SCRT using modern image-guided intensity-modulated radiation therapy (IG-IMRT) could potentially intensify local therapy and subsequently improve outcomes. The primary objective of this phase I trial was to define the maximum tolerated dose (MTD) of the HFRT boost with concurrent weekly C/P following SCRT. Patients (pts) who were inoperable or medically unresectable and metastatic with life expectancy ≥ 4 months were eligible. The lower thoracic esophageal cancer involving the stomach was ineligible. Pts were treated with weekly P at 45 mg/m2 and C area under the curve 1.5 with concurrent 50 Gy of IG-IMRT given in 25 fractions for 5 weeks, immediately followed by an image-guided intensity-modulated HFRT boost to the GTV concurrent with the same chemotherapy regimen. The boost doses were escalated ranging from 7.2 to 43.2 Gy in increments of 7.2 Gy delivered in 6 twice daily fractions of 1.2 Gy using a modified Fibonacci design. A minimum of 6 weeks follow-up was required after completion of radiation treatment before proceeding to the next dose. Dose limiting toxicity (DLT) was defined as grade ≥ 4 esophagitis or any other grade ≥ 3 non-hematological toxicity (except nausea and vomiting) or grade ≥ 4 hematological toxicity lasting more than 7 days, which are possibly, probably or definitely associated with protocol treatment occurring during and after completion of the HFRT boost treatment. The MTD was defined as the highest radiation dose at which ≤ 1 pts experienced DLT. Once the MTD was determined, this cohort was expanded to further define the safety profile. Adjuvant chemotherapy was optional. Thirty-four pts were enrolled and 31 were assessable (median age, 62 years; 73% male; 97% T3-4 disease, 65% N1-2 disease; 9% M1 disease; 97% squamous cell carcinoma; 90% PS 0-1).SCRT was well tolerated. The incidence of DLT was 0/3, 0/3, 0/3, 1/6 (grade 4 esophagitis), 0/3, 2/3 (grade 5 esophageal fistula and grade 3 pneumotitis each) at 7.2, 14.4, 21.6, 28.8, 36, and 43.2 Gy, respectively, thus defining the MTD at 36 Gy. In the expansion cohort of 10 pts at the MTD, no DLTs were encountered. The most common acute grade 3 or greater toxicities throughout the entire study period were esophagitis (26%) and neutropenia (19%). Late toxicity included grade 2 esophageal stricture (n = 4). The overall response rate was 84% (95% CI, 42% to 93%; 100% at a dose of ≥ the MTD). With a median follow up of 5 months (range 1 to 12 months), no LF was observed, and distant failure occurred in 3 pts. The MTD of a HFRT boost was determined to be 36 Gy using IG-IMRT with concurrent P and C following 50 Gy of SCRT, resulting in the total combined tumor dose of 86 Gy. Preliminary efficacy data are encouraging. A Phase II study to further evaluate this regimen is underway.

Do Higher Radiation Doses with Concurrent Chemotherapy in the Definitive Treatment of Esophageal Cancer Improve Outcomes? A Meta-Analysis and Systematic Review

Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy.

High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis

Phase I Study of Dose-Escalated Intensity-Modulated Hyperfractionated Radiation Therapy (HFRT) Boost with Concurrent Paclitaxel (P) and Carboplatin (C) to Gross Tumor Volume (GTV) Following Standard-Dose Chemoradiotherapy (SCRT) for Advanced Esophageal Ca

Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03)

Radiation dose escalation can improve local disease control and survival among esophageal cancer patients with large primary tumor volume receiving definitive chemoradiotherapy

A Meta-Analysis and Review of Radiation Dose Escalation in Definitive Radiation Therapy between Squamous Cell Carcinoma and Adenocarcinoma of Esophageal Cancer

Do the patients with esophageal cancer benefit from higher radiation dose?——Dose escalation of 3-D conformal radiation therapy in the patients with esophageal cancer

Impact of Radiation Dose on Survival for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy

[A multicenter randomized prospective study of concurrent chemoradiation with 60 Gy versus 50 Gy for inoperable esophageal squamous cell carcinoma].

Do higher radiation doses improve survival for cervical esophageal squamous cell cancer patients treated with definitive chemoradiotherapy using intensity-modulated radiotherapy? A propensity-score matched analysis

Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial

Radiation Dose-Effect Relation in Patients with Esophageal Squamous Cell Carcinoma: A National Cancer Center Data and Literature-Based Analysis

Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis

Long Term Results of Different Radiotherapy Techniques and Fractions for Esophageal Squamous Cell Carcinoma

High-dose versus standard-dose intensity-modulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, phase 3 superiority trial

Dose escalation in radical radio(chemo)therapy for cervical and upper thoracic esophageal cancer with 3DCRT/IMRT (ChC&UES): a multicenter retrospective study

Chemoradiotherapy Versus Chemotherapy Alone for Advanced Esophageal Squamous Cell Carcinoma: The Role of Definitive Radiotherapy for Primary Tumor in the Metastatic Setting

Long-Term Outcomes of Three-Dimensional Conformal Radiation Therapy Without Chemotherapy for Esophageal Squamous Cell Carcinoma: A Final Report of a Phase 2 Study

A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma

Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity